helicobacter pylori infection
Conditions
Interventions
Group B:Doxycycline dual therapy
Group A:Bismuth quadruple solution
Sponsors
NanJing First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18-65 years old; 2. Patients diagnosed as positive for Helicobacter pylori by 13C-UBT or 14C-UBT; 3. Patients who have previously received dual therapy containing amoxicillin to eradicate Hp; 4. Voluntarily join this trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergic to the studied drugs (such as furazolidone, vonoprazan, doxycycline, etc.); 2. Identify patients with active peptic ulcers; 3. Patients who have not received Helicobacter pylori eradication treatment before; 4. Patients who have previously received bismuth quadruple therapy containing furazolidone, tetracycline and tetracycline antibiotics to eradicate Hp; 5. Antibiotics and bismuth agents should be used 4 weeks before the start of the study treatment, and histamine H2 receptor antagonists or PPIs should be used 2 weeks before the start. 6. Use adrenal cortical hormones, non-steroidal anti-inflammatory drugs, anticoagulants, barbiturates, phenytoin or carbamazepine and other drugs; 7. History of esophageal or gastric surgery; 8. Pregnant and lactating women; 9. Alcoholism; 10. Suffering from serious concomitant diseases, such as liver diseases, cardiovascular diseases, lung diseases, and kidney diseases; 11. Those with liver dysfunction caused by hepatitis, fatty liver and other reasons; 12. Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hp eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety observation;Fecal genetic testing; | — |
Countries
China
Contacts
Public ContactZhangZhenyu
NanJing First Hospital
Outcome results
None listed